Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma overview

Gene therapy is under development for the treatment of R/R B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, mucosa-associated lymphoid tissue or malt-lymphoma, burkitt lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, diffuse large b-Cell lymphoma, relapsed and refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. It is a chimeric antigen receptor modified-T cell (CART). The therapeutic candidate acts by targeting cells expressing CD19 and CD22. It is administered through parenteral route.

Hebei Senlang Biotechnology overview

Hebei Senlang Biotechnology is a pharamaceutial and healthcare company which is involved in using bio technology for treatment of immune cells. The company is headquartered in Dongguan, Hebei, China.

For a complete picture of Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.